

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Link-Asia International MedTech Group Limited**

**環亞國際醫療科技集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1143)**

### **GRANT OF SHARE OPTIONS**

This announcement is made by Link-Asia International MedTech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces that on 14 June 2022 (the “**Date of Grant**”), the Company offered to grant 53,328,000 share options (the “**Share Option(s)**”) to certain employees of the Group (collectively, the “**Grantees**”) to subscribe for an aggregate of 53,328,000 shares of HK\$0.02 each in the share capital of the Company (the “**Share(s)**”) subject to and upon the terms and conditions of the share option scheme adopted by the Company on 10 March 2020. Details of the Share Options granted are set out as follows:

Details of the grant of the Share Options are as follows:

Date of Grant:	14 June 2022
Number of the Share Options granted:	53,328,000 Share Options
Exercise price of the Share Options granted:	HK\$0.106 to subscribe for one Share
Closing price of the Shares on the Date of Grant:	HK\$0.106 per Share
Validity period of the Share Options:	14 June 2022 to 13 June 2024 (two (2) years), both days inclusive
Vesting period of the Share Options:	The options shall be exercisable immediately on the Date of Grant

Each Share Option shall entitle the holder of the Share Option to subscribe for one Share upon exercise of such Share Option at an exercise price of HK\$0.106 per Share, which represents the highest of: (1) the closing price of HK\$0.106 per Share as stated in the daily quotations sheet issued by the Stock Exchange on the Date of Grant; (2) the average closing price of HK\$0.1012 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant and (3) the nominal value of the Share of HK\$0.02.

None of the Grantees of the aforesaid options granted is a director, chief executive or substantial shareholder of the Company, nor an associate (as defined under the Listing Rules) of any of them.

On behalf of the Board  
**Link-Asia International MedTech Group Limited**  
**Lin Dailian**  
*Chairman and executive Director*

Hong Kong, 14 June 2022

*As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.*